Rheumatologists are right to be sceptical of claims that biosimilars are equivalent to bio-originator molecules because the evidence is either lacking or flawed, the ARA conference in Melbourne heard. Professor Roy Fleischmann, a Texas-based rheumatologist who has been lead investigator in many clinical trials of biologics, said there was some evidence to show biosimilars may ...
Biosimilars equivalence data is lacking, especially for switching: international expert
By Michael Woodhead
8 May 2018